

MGM INSTITUTE OF HEALTH SCIENCES

(Deemed University u/s 3 of UGC Act, 1956) Grade 'A' Accredited by NAAC

MGM NEW BOMBAY COLLEGE OF NURSING

5th Floor, MGM Educational Campus, Plot No. 1& 2, Sector-1 Kamothe, Navi Mumbai – 410 209

List of PG Students presented in the Ethical Committee of MGM Dental College & Hospital on 29.06.2022

Sr. No	Name of the Student	Title of the Study	IEC-Reference Number
1	Ms. Komal Kathare	Effectiveness of synchronous versus asynchronous learning methodology on knowledge of intra-aortic balloon pump among nursing students	MGM/DCH/IEC/064/22
2	Ms. Ankita Mokal	Effect of flex model of blended learning on knowledge and skill of triage management among nursing students	MGM/DCH/IEC/065/22
3	Ms. Aarti Patil	Effect of Insert learning application on knowledge related to burn management among undergraduate nursing students	MGM/DCH/IEC/066/22
4	Mr. Mahesh Pardeshi	Develop and validate shift handover application for nurses	MGM/DCH/IEC/067/22
5	Ms. Shraddha Rane	Develop and validate online jigsaw puzzle technique on metabolism pathway of nutrients for undergraduate nursing students	MGM/DCH/IEC/068/22
6	Ms. Mansi Kambali	Effect of web-based learning module on knowledge related to drug calculation among staff nurses in teaching hospital	MGM/DCH/IEC/069/22
7	Ms. Tejal Karlekar	Effect of reflective thinking practice on basic procedural skill among first year undergraduate nursing student	MGM/DCH/IEC/070/22
8	Ms.Minakshi Musale	Effect of simulation on knowledge and skill in ECG interpretation among final year BSc Nursing students	MGM/DCH/IEC/071/22
9	Ms. Shaila Ghanekar	Develop and validate central line catheter insertion checklist for critically ill patients admitted in intensive care units of the teaching hospital of Navi Mumbai	MGM/DCH/IEC/072/22

Dr.(Mrs) Prabha K Dasila 41020

Professor & Director



Junction of NH-4 and Sion Panvel Expressway, Sector-01,
Kamothe, Navi Mumbai- 410 209
Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/

064 /22

Date: 22/ 7/2022

To.

Ms. Komal Kathare

MGM New Bombay College of Nursing

Guide: Mrs. Sarika Nair

Kamothe, Navi Mumbai- 410209

Reference:

1. Your submission of Dissertation studyprotocol

2. Study Title: Effectiveness of Synchronous Versus Asynchronous learning methodology on knowledge of Intra Aortic Balloon Pump among nursing students: A comparative study

3. IEC-MGMDCH referenceno MGM/DCH/IEC/064/22

Dear Ms. Komal Kathare

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

- Application to IERC MGMDCH dt.4/5/2022
- 2. Summary of researchprotocol
- 3. Research protocol (Version 1dt 4/5/2022)
- Amendments to research protocol (No 4Dt...../...../2022) N/A
- 5. Informed consent document (ICD) in English (Version...1..dt.A./.5..../2022)
- 6. ICD in Hindi language translated from English (Version ...l....dt. .H./.5.../2022)
- 8. Back translations of ICD from Hindi to English (Version...1..dt...4./...5./2022)
- 9. Back translations of ICD from Marathi to English (Version...l...dt...4./...5.../2022)
- 10. Amendments to the ICD (Version,dt..../2022)
- 11. Case Record Form (CRF) / Study Questionnaire / StudyProforma ~
- 12. Principal investigators Current Curriculum Vitae (signed anddated)
- 13. Subject recruitment procedures: advertisement, letters to doctors, notices NA
- 14. Investigator Brochure (IB) applicable for investigational new drugs(IND) NA
- 15. Ethics Committee clearance of other study centers (Total No.) NA
- 16. Insurance policy ifany NA
- 17. Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA
- 18. Investigator's undertaking to DCG(I) ifapplicable NA
- 19. Health Ministry Screening Committee (HMSC) approval ifapplicable NA
- 20. Bhabha Atomic Research Centre (BARC) approval ifapplicable NA
- 21. Genetic Engineering Advisory Committee (GEAC) approval ifapplicable NA
- 22. Director General of Foreign Trade (DGFT) approval ifapplicable NA
- 23. FDA marketing/manufacturing license for herbal drugs. ifapplicable NA
- 24. Other Documents(specify.....) PageNo



-122, 12.00 FIVE

INSTITUTIONAL ETHICS COMMITTEE MAHATMA GANDHI MISSION'S DENTAL COLLEGE & HOSPITAL

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: lercmgmdch@gmail.com

MGM/DCH/ IEC /

064 /22

Date: -22/7/2022

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker



Y ZIYU AIIU ORU FAGE.QOCX - GOOGIE DOCS

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/ IEC /

064

122

Date: - 22/ 7/2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/

065 122

Date: - 22/7/2022

To.

Mrs. Ankita B. Mokal

MGM New Bombay College of Nursing

Guide: Mrs. Sarika Nair

Kamothe, Navi Mumbai- 410209

Reference:

1. Your submission of Dissertation studyprotocol

2. Study Title: Conventional teaching versus flex model of blended learning on knowledge and skill of triage management among nursing students: A comparative study

3. IEC-MGMDCH referenceno MGM/DCH/TEC/065/22

Dear Mrs. Ankita B. Mokal

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

- 1. Application to IERC MGMDCH dt.4/5/2022
- 2. Summary of researchprotocol
- 3. Research protocol (Version 1dt 4/5/2022)
- Amendments to research protocol (No 4Dt...../...../2022) N/A 4.
- 5. Informed consent document (ICD) in English (Version..1...dt..4./.5.../2022)
- ICD in Hindi language translated from English (Versionl...dt. ...4./.5.../2022) 6.
- ICD in Marathi language translated from English (Version..1...dt...4../.5.../2022) 7.
- 8.
- Back translations of ICD from Hindi to English (Version.......dt...4./...5../2022) 9.
- Back translations of ICD from Marathi to English (Version...dt. 4.../5..../2022)
- 10. Amendments to the ICD (Version,dt..../2022)
- Case Record Form (CRF) / Study Questionnaire / StudyProforma 🛩 11.
- Principal investigators Current Curriculum Vitae (signed anddated) 12.
- 13. Subject recruitment procedures: advertisement, letters to doctors, notices NA
- Investigator Brochure (IB) applicable for investigational new drugs(IND) NA 14.
- Ethics Committee clearance of other study centers (Total No.) NA 15.
- 16. Insurance policy ifany NA
- Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA 17.
- 18. Investigator's undertaking to DCG(I) ifapplicable NA
- Health Ministry Screening Committee (HMSC) approval ifapplicable NA 19.
- Bhabha Atomic Research Centre (BARC) approval ifapplicable NA 20.
- Genetic Engineering Advisory Committee (GEAC) approval ifapplicable N♣ 21.
- Director General of Foreign Trade (DGFT) approval ifapplicable NA 22.
- FDA marketing/manufacturing license for herbal drugs. ifapplicable NA 23.
- 24. Other Documents(specify.....) PageNo



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/

065 / 22

Date: -22/ 7/2022

The following members of the Ethics committee discussed the study documents and voted at the meeting:

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker

DECISION . spproved

Page No.2



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/

065 / 22

Date: - 22 / 7 /2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/

066 / 22

Date: - 22 / 7/2022

To,

Ms. Aarti Patil

MGM New Bombay College of Nursing Guide: Mrs. Sarika Nair, Dr. Swati Sinha Kamothe, Navi Mumbai-410209

Reference:

1. Your submission of Dissertation studyprotocol

2. Study Title: Effect of Insert Learning Application and conventional teaching on knowledge related to burn management among undergraduate nursing students: A comparative study

3. IEC-MGMDCH referenceno MGM/DCH | TEC/ 066 | 22

Dear Ms. Aarti Patil

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

Application to IERC MGMDCH dt.4/5/2022

2. Summary of researchprotocol

3. Research protocol (Version 1dt 4/5/2022)

4. Amendments to research protocol (No 4Dt.....//2022) N/A

6. ICD in Hindi language translated from English (Version dt. ... /2022)

7. ICD in Marathi language translated from English (Version. 1...dt. 1./5.../2022)
8. Back translations of ICD from Hindi to English (Version. 1...dt. 1./.5.../2022)

9. Back translations of ICD from Marathi to English (Version...l....dt...4./5.../2022)

10. Amendments to the ICD (Version,dt..../2022)

11. Case Record Form (CRF) / Study Questionnaire / Study Proforma

12. Principal investigators Current Curriculum Vitae (signed anddated)

Subject recruitment procedures: advertisement, letters to doctors, notices NA
 Investigator Brochure (IB) – applicable for investigational new drugs(IND)NA

15. Ethics Committee clearance of other study centers (Total No.) NA

16. Insurance policy ifany NA

17. Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA

18. Investigator's undertaking to DCG(I) ifapplicable NA

Health Ministry Screening Committee (HMSC) approval ifapplicable NA
 Bhabha Atomic Research Centre (BARC) approval ifapplicable NA

Bhabha Atomic Research Centre (BARC) approval ifapplicable NA
 Genetic Engineering Advisory Committee (GEAC) approval ifapplicable NA

22. Director General of Foreign Trade (DGFT) approval ifapplicable NA

23. FDA marketing/manufacturing license for herbal drugs. ifapplicable NA

24. Other Documents(specify.....) PageNo



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: lercmgmdch@gmail.com

MGM/DCH/IEC/ 066 / 22

Date: - 21/7 /2022

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langac	
2.	Dr. Prakash Khandel	wal Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Pravee	n Scientific
5.	Adv. Dr. Sheela Hosar	nani Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath V	K Scientific
8.	Dr. Ashvini Padhyo	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Vargl	hese Lay person
11.	Dr. Sabitha Praveer	1 Biostatistician
12.	Mrs. Rupali Gujar	Social worker



LETTER ZIND BING SKD PAGE. GOOK - GOOGIE DOCS

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/ IEC /

066 / 22

Date: - 22/ 7/2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- 1. Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



Junction of NH-4 and Sion Panvel Expressway, Sector-01,
Kamothe, Navi Mumbai- 410 209
Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/ 067 / 22

Date: - 22/7/2022

PageNo

To,

23.

24.

Mr. Mahesh Pardeshi

MGM New Bombay College of Nursing

Guide: Mrs. Sivakama Sundari, Dr. Sanjay Waykar

Kamothe, Navi Mumbai- 410209

Reference:

1. Your submission of Dissertation studyprotocol

2. Study Title: Develop and validate shift handover application for nurses

3. IEC-MGMDCH referenceno MGM | DCH | IEC | 067 | 22

Dear Mr. Mahesh Pardeshi

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

I OHO	wing documents were reviewed in the meeting held on date 29/6/2022
1.	Application to IERC MGMDCH dt.4/5/2022
2.	Summary of researchprotocol
3.	Research protocol (Version 1dt 4/5/2022)
4.	Amendments to research protocol (No 4Dt/2022) N/A
5.	Informed consent document (ICD) in English (Versiondt/2022)
6.	ICD in Hindi language translated from English (Versiondt/2022)
7.	ICD in Marathi language translated from English (Versiondt/2022)
8.	Back translations of ICD from Hindi to English (Versiondt/2022)
9.	Back translations of ICD from Marathi to English (Versiondt/ /2022)
10.	Amendments to the ICD (Versiondt/2022)
11.	Case Record Form (CRF) / Study Questionnaire / StudyProforma
12.	Principal investigators Current Curriculum Vitae (signed anddated)
13.	Subject recruitment procedures: advertisement, letters to doctors notices NA
14.	Investigator Brochure (IB) – applicable for investigational new drugs(IND) NA
15.	Ethics Committee clearance of other study centers (Total No.) NA
16.	Insurance policy ifany NA
17.	Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA
18.	Investigator's undertaking to DCG(I) ifapplicable NA
19.	Health Ministry Screening Committee (HMSC) approval ifamplicable NA
20.	Bhabha Atomic Research Centre (BARC) approval ifapplicable
21.	Genetic Engineering Advisory Committee (GEAC) approval ifapplicable NA
22.	Director General of Foreign Trade (DGFT) approval ifapplicable NA
22	PD.

FDA marketing/manufacturing license for herbal drugs. ifapplicable NA

Other Documents(specify.....)



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: lercmgmdch@gmail.com

MGM/DCH/IEC/ 067 / 22

Date: - 22/ 7 /2022

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker



EIND AIR SIND FAGE. GOOK - GOOGIG DOGS

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/ IEC /

067 / 22

Date: - 22/7 /2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



INSTITUTIONAL ETHICS COMMITTEE

MAHATMA GANDHI MISSION'S DENTAL COLLEGE & HOSPITAL

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/

068

1 22

Date: - 22/7 /2022

PageNo

To,

23.

24.

Mrs. Shraddha Rane

MGM New Bombay College of Nursing

Guide: Mrs. Sivakama Sundari, Mr. Sachin Chavan

Kamothe, Navi Mumbai- 410209

Reference:

1. Your submission of Dissertation studyprotocol

- 2. Study Title: Develop and validate online jigsaw puzzle technique on metabolism pathway of nutrients for undergraduate students
- 3. IEC-MGMDCH referenceno MCM/DCH/IEC/068/22

Dear Mrs. Shraddha Rane

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

. 0110	mg documents were reviewed in the meeting field on date 29/6/2022
1.	Application to IERC MGMDCH dt.4/5/2022
2.	Summary of researchprotocol
3.	Research protocol (Version 1dt 4/5/2022)
4.	Amendments to research protocol (No 4Dt//2022) N/A
5.	Informed consent document (ICD) in English (Versiondt/2022)
6.	ICD in Hindi language translated from English (Version dt / /2022)
7.	ICD in Marathi language translated from English (Versiondt/2022)
8.	Back translations of ICD from Hindi to English (Version dt / /2022)
9.	Back translations of ICD from Marathi to English (Versiondt / /2022)
10.	Amendments to the ICD (Version, dt/2022)
11.	Case Record Form (CRF) / Study Questionnaire / StudyProforma
12.	Principal investigators Current Curriculum Vitae (signed anddated)
13.	Subject recruitment procedures: advertisement, letters to doctors notices NA
14.	Investigator Brochure (IB) – applicable for investigational new drugs(IND) NA
15.	Ethics Committee clearance of other study centers (Total No.) NA
16.	Insurance policy ifany NA
17.	Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA
18.	Investigator's undertaking to DCG(I) ifapplicable NA
19.	Health Ministry Screening Committee (HMSC) approval ifamplicable NA
20.	Bhabha Atomic Research Centre (BARC) approval ifapplicable NA
21.	Genetic Engineering Advisory Committee (GEAC) approval if applicable NA
22.	Director General of Foreign Trade (DGFT) approval ifapplicable NA
22	EDA modulation / Coldinate

FDA marketing/manufacturing license for herbal drugs. ifapplicable NA

Other Documents(specify.....)



THE TAGE LETTER ZIND AND PAGE GOCK - GOOGIE DOCK

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/ 068


1 22

Date: -22/7/2022

The following members of the Ethics committee discussed the study documents and voted at the meeting:

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker

DECISION Approved





Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/ IEC /

068

1 22

Date: - 22 / 7 /2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- 1. Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/

069

1 22

Date: - 22 /7 /2022

To.

Ms. Mansi Kambli

MGM New Bombay College of Nursing

Guide: Mrs. Sivakama Sundari, Dr. Ashok Kanthe

Kamothe, Navi Mumbai- 410209

Reference:

1. Your submission of Dissertation studyprotocol

2. Study Title: Effect of web based learning module on knowledge related to drug calculations among staff nurses in teaching hospital: A quasi-experimental study

3. IEC-MGMDCH referenceno MGM/DCH/IEC/069/22

Dear Ms. Mansi Kambli

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

- 1. Application to IERC MGMDCH dt.4/5/2022
- 2. Summary of researchprotocol
- 3. Research protocol (Version 1dt 4/5/2022)
- Amendments to research protocol (No 4Dt...../2022) N/A
- 5. Informed consent document (ICD) in English (Version..l...dt...4/..5.../2022)
- 6. ICD in Hindi language translated from English (Version ...l....dt. H.../.5. /2022)
- 7. ICD in Marathi language translated from English (Version.1....dt..4.../5..../2022)
- 8. Back translations of ICD from Hindi to English (Version...\..dt. 4./..\.\.5. /2022)
- 9. Back translations of ICD from Marathi to English (Version. 1...dt. 4./.5.../2022)
- 10. Amendments to the ICD (Version,dt..../2022)
- Case Record Form (CRF) / Study Questionnaire / StudyProforma
- 12. Principal investigators Current Curriculum Vitae (signed anddated)
- 13. Subject recruitment procedures: advertisement, letters to doctors, notices NA
- 14. Investigator Brochure (IB) applicable for investigational new drugs(IND) NA
- 15. Ethics Committee clearance of other study centers (Total No.) NA
- 16. Insurance policy ifany NA
- 17. Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA
- 18. Investigator's undertaking to DCG(I) ifapplicable NA
- 19. Health Ministry Screening Committee (HMSC) approval ifapplicable NA
- 20. Bhabha Atomic Research Centre (BARC) approval ifapplicable NA
- 21. Genetic Engineering Advisory Committee (GEAC) approval ifapplicable NA
- 22. Director General of Foreign Trade (DGFT) approval ifapplicable NA
- 23. FDA marketing/manufacturing license for herbal drugs. ifapplicable NA
- 24. Other Documents(specify.....)

PageNo



ATTO ATTO OTTO FACE LUCK - GOUGHE DUCK

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/ 069 / 22

Date: -22/7/2022

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker



LETTEN ZIND BIID OND PAGE.COCX - GOOGIE DOCS

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/ IEC /

069 / 22

Date: - 22/7 /2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- 1. Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022-27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/

1 22 070

Date: - 22/7/2022

To.

Mrs. Tejal Karlekar

MGM New Bombay College of Nursing

Guide: Mrs. FerganziaJubilson Kamothe, Navi Mumbai- 410209

Reference:

1. Your submission of Dissertation studyprotocol

2. Study Title: Effect of Reflective Thinking Practice on basic procedural skill among First Year Undergraduate Nursing students

3. IEC-MGMDCH referenceno MGM DCH IEC |070 | 22

Dear Mrs. Tejal Karlekar

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

- 1. Application to IERC MGMDCH dt.4/5/2022
- 2. Summary of researchprotocol
- 3. Research protocol (Version 1dt 4/5/2022)
- Amendments to research protocol (No 4Dt...../2022) N/A 4.
- 5. Informed consent document (ICD) in English (Version...dt..4./.5.../2022)
- ICD in Hindi language translated from English (Versiondt. 4.../.5.. /2022) 6.
- ICD in Marathi language translated from English (Version.1....dt..4.../5.../2022) 7.
- Back translations of ICD from Hindi to English (Version...1...dt...4./..5.../2022) 8.
- 9. Back translations of ICD from Marathi to English (Version...l....dt...4./6..../2022)
- Amendments to the ICD (Version,dt..../2022) 10.
- Case Record Form (CRF) / Study Questionnaire / StudyProforma 11.
- Principal investigators Current Curriculum Vitae (signed anddated) 12.
- Subject recruitment procedures: advertisement, letters to doctors, notices NA 13.
- 14. Investigator Brochure (IB) - applicable for investigational new drugs(IND) NA
- Ethics Committee clearance of other study centers (Total No.) NA 15.
- 16. Insurance policy ifany NA
- Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA 17.
- Investigator's undertaking to DCG(I) ifapplicable NA 18.
- Health Ministry Screening Committee (HMSC) approval ifapplicable A 19.
- Bhabha Atomic Research Centre (BARC) approval ifapplicable NA 20.
- Genetic Engineering Advisory Committee (GEAC) approval ifapplicable NA 21.
- Director General of Foreign Trade (DGFT) approval ifapplicable NA 22.
- 23. FDA marketing/manufacturing license for herbal drugs. ifapplicable NA
- 24. Other Documents(specify.....) PageNo



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/

070 / 22

Date: -22/7 /2022

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker



ETTEN ZIND BIID SKU PAGE. GOCX - GOOGIE DOCS

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tei: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/ 070 /22

Date: - 22/7 /2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- 1. Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



Junction of NH-4 and Sion Panvel Expressway, Sector-01,
Kamothe, Navi Mumbai- 410 209
Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/ 071 / 22

Date: - 22/7/2022

To, Ms. Minakshi DattaraoMusale MGM New Bombay College of Nursing Guide: Mrs. Susan Jacob Kamothe, Navi Mumbai-410209

Reference:

1. Your submission of Dissertation studyprotocol

2. Study Title: Effect of Traditional teaching versus Simulation based learning on knowledge and skill in ECG interpretation among Final year BSc Nursing students: A comparative study

3. IEC-MGMDCH referenceno MGM | DCH | IEC | 071 | 22

Dear Ms. Minakshi Musale

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

- 1. Application to IERC MGMDCH dt.4/5/2022
- 2. Summary of researchprotocol
- Research protocol (Version 1dt 4/5/2022)
- 4. Amendments to research protocol (No 4Dt...../2022) N/A
- 5. Informed consent document (ICD) in English (Version...1..dt. 4../.5.../2022)

 6. ICD in Hindi language translated from English (Version...1..dt. 4../.5.../2022)
- 6. ICD in Hindi language translated from English (Version ...)...dt. .4./5.../2022)
- 8. Back translations of ICD from Hindi to English (Version...1..dt...1./.5.../2022)
- 9. Back translations of ICD from Marathi to English (Version...\u00e4...\u00e41...\u00e41...\u00e42...\u00e42022)
- 10. Amendments to the ICD (Version,dt..../2022)
- 11. Case Record Form (CRF) / Study Questionnaire / StudyProforma
- 12. Principal investigators Current Curriculum Vitae (signed anddated)
- 13. Subject recruitment procedures: advertisement, letters to doctors, notices NA
- 14. Investigator Brochure (IB) applicable for investigational new drugs(IND) A
- 15. Ethics Committee clearance of other study centers (Total No.) NA
- 16. Insurance policy ifany NA
- 17. Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA
- 18. Investigator's undertaking to DCG(I) ifapplicable NA
- 19. Health Ministry Screening Committee (HMSC) approval ifapplicable NA
- 20. Bhabha Atomic Research Centre (BARC) approval ifapplicable NA
- 21. Genetic Engineering Advisory Committee (GEAC) approval ifapplicable NA
- 22. Director General of Foreign Trade (DGFT) approval ifapplicable NA
- 23. FDA marketing/manufacturing license for herbal drugs. ifapplicable NA
- 24. Other Documents(specify.....) PageNo



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/ 071 /22

Date: -22/ 7/2022

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker



LET TEN AND AND PAGE GOCK - GOOGIE DOCS

Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: lercmgmdch@gmail.com

MGM/DCH/ IEC /

071 / 22

Date: - 22/7 /2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- 1. Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,



Junction of NH-4 and Sion Panvel Expressway, Sector-01,
Kamothe, Navi Mumbai- 410 209
Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail:mgmdch@mgmmumbai.ac.in

MGM/DCH/IEC/ 072

122

Date: - 22/7/2022

PageNo

To,

Ms. Shaila Ghanekar

MGM New Bombay College of Nursing Guide: Mrs. Preethi Maria Mathew Kamothe, Navi Mumbai- 410209

Reference:

22.

23.

24.

1. Your submission of Dissertation studyprotocol

- 2. Study Title: Develop and validate Central Line Catheter Insertion Checklist for critically ill patients admitted in Intensive Care Units of the teaching hospital of Navi Mumbai
- 3. IEC-MGMDCH referenceno MGM | DCH | TEC | 072/22

Dear Ms. Shaila Ghanekar

The IEC- MGMDCH has received and reviewed your submission

Following documents were reviewed in the meeting held on date 29/6/2022

1 0110	wing documents were reviewed in the meeting held on date 29/6/2022
1.	Application to IERC MGMDCH dt.4/5/2022
2.	Summary of researchprotocol
3.	Research protocol (Version 1dt 4/5/2022)
4.	Amendments to research protocol (No 4Dt/2022) N/A
5.	Informed consent document (ICD) in English (Versiondt/2022)
6.	ICD in Hindi language translated from English (Versiondt/2022)
7.	ICD in Marathi language translated from English (Versiondt/2022)
8.	Back translations of ICD from Hindi to English (Versiondt/2022)
9.	Back translations of ICD from Marathi to English (Versiondt/2022)
10.	Amendments to the ICD (Version,dt/2022)
11.	Case Record Form (CRF) / Study Questionnaire / StudyProforma
12.	Principal investigators Current Curriculum Vitae (signed anddated)
13.	Subject recruitment procedures: advertisement, letters to doctors, notices NA
14.	Investigator Brochure (IB) – applicable for investigational new drugs(IND)NA
15.	Ethics Committee clearance of other study centers (Total No.) NA
16.	Insurance policy ifany NA
17.	Drugs Controller General (India) [DCG(I)] clearance ifapplicable NA
18.	Investigator's undertaking to DCG(I) ifapplicable NA
19.	Health Ministry Screening Committee (HMSC) approval ifapplicable NA
20.	Bhabha Atomic Research Centre (BARC) approval ifapplicable NA
21.	Genetic Engineering Advisory Committee (GEAC) approval ifapplicable NA
22	Director Council of F T. J. (DCDC)

Director General of Foreign Trade (DGFT) approval ifapplicable NA

Other Documents(specify.....)

FDA marketing/manufacturing license for herbal drugs. ifapplicable NA



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/ IEC /

072

1 22

Date: - 22/ 7 /2022

Sr.No	Name	Role and Responsibility
1.	Dr. Deepak Langade	Chairman, Scientific
2.	Dr. Prakash Khandelwal	Co-Chairperson, Scientific
3.	Dr. Shilpa Patel	Member Secretary
4.	Dr. Sabitha Praveen	Scientific
5.	Adv. Dr. Sheela Hosamani	Scientific, Legal
6.	Dr. Shilpa Patel	Scientific, Woman
7.	Dr. Ravindranath VK	Scientific
8.	Dr. Ashvini Padhye	Scientific, Woman
9.	Dr. Jyoti Nadgere	Scientific, Woman
10.	Dr. Nithya Eldho Varghese	Lay person
11.	Dr. Sabitha Praveen	Biostatistician
12.	Mrs. Rupali Gujar	Social worker



Junction of NH-4 and Sion Panvel Expressway, Sector-01, Kamothe, Navi Mumbai- 410 209 Tel: 022- 27436604; Fax: 91-22-27433185; E-Mail: iercmgmdch@gmail.com

MGM/DCH/IEC/ 072 / 22

Date: - 22/7 /2022

Based on the discussion of the submitted documents for the scientific and ethical review, we approve the research protocol to be conducted and its presented form subject to the following conditions:

- 1. Applicable and mandatory regulatory permissions to be obtained prior to commencement of the study i.e. registration at clinical trial registry of India. (www.ctri.nic.in)
- 2. The investigators and other participants should be adequately trained on the protocol and its related procedures, the Good Clinical Practices (GCP) guidelines prior to commencing the study.
- Participating subjects should be adequately enlightened about the protocol during informed consent process and under insurance coverage in an event of any trial related injury/accident.
- 4. Participating subjects should not be put to additional financial burden related to the study protocol.
 - The validity of this approval is for two years from date of approval. Within this period, the Institutional Ethics Committee expects to be periodically informed about the following:
 - The progress of the study
 - Any Serious Adverse Event (SAE) occurring in the course of the study
 - Any significant changes in the protocol/patient information/ informed consent
 - Update on safety of the investigating product or procedure
 - To provide an abridge copy of the final report after completion of the study
- 5. It is mandatory for the investigators affiliated with other institutions to provide a letter of approval from the Ethics Committee of the respective institution.

Thanking you Yours Sincerely,